Faeth Therapeutics, Inc.

FTH Healthcare Biotechnology

In the quarter to June 2026, EPS grew 27.4% and free cash flow fell 174.2%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

18.79 1.81 −8.79%
Market cap
$532.3M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Current Ratio
— 0.48 0.02 4.16 30.38 11.98 11.92 7.70 5.06
Net Debt/EBITDA
— (0.32) (1.44) 0.90 3.97 2.16 1.82 1.32 0.96
Debt/Equity
— (0.80) (0.23) (0.01) 0.01 0.02 0.01 0.00 0.00
ROE
— 27.58% 33.64% 32.30% (81.70%) (38.88%) (40.52%) (58.40%) (74.01%)
ROA
— (1,820.86%) (1,339.68%) (178.44%) (42.13%) (35.78%) (35.38%) (50.37%) (61.78%)
ROIC
— 0.00% 0.00% 0.00% (4,138.91%) 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
— 1,336.75% 98.09% (122.36%) (24.81%) (47.84%) (54.33%) (81.73%) (121.61%)
Free Cash Flow per Share
— (0.35) (468.70) (234.63) (23.07) (25.62) (22.92) (19.76) (16.03)
Book value per Share
— (0.20) (3,731.63) (700.29) 105.74 67.36 46.43 30.56 14.74
Free Cash Flow
— (10.31) (8.62) (18.91) (31.97) (39.33) (32.04) (24.82) (20.22)
Other line items

Show all line items

Columns are period end dates